Recursion Pharmaceuticals Inc (RXRX) - Total Assets
Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) holds total assets worth $1.34 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore RXRX operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Recursion Pharmaceuticals Inc - Total Assets Trend (2019–2025)
This chart illustrates how Recursion Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See RXRX net assets for net asset value and shareholders' equity analysis.
Recursion Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Recursion Pharmaceuticals Inc's total assets of $1.34 Billion consist of 55.1% current assets and 44.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 50.4% |
| Accounts Receivable | $24.65 Million | 1.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $309.90 Million | 21.0% |
| Goodwill | $162.16 Million | 11.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Recursion Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Recursion Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Recursion Pharmaceuticals Inc's current assets represent 55.1% of total assets in 2025, a decrease from 75.3% in 2019.
- Cash Position: Cash and equivalents constituted 50.4% of total assets in 2025, down from 68.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 32.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 21.0% of total assets.
Recursion Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Recursion Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Recursion Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.47 | 4.11 | 21.92 |
| Quick Ratio | 5.47 | 4.11 | 21.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $579.86 Million | $442.16 Million | $618.10 Million |
Recursion Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Recursion Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.72 |
| Latest Market Cap to Assets Ratio | 1.07 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | $1.47 Billion |
| Market Capitalization | $1.57 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Recursion Pharmaceuticals Inc's assets above their book value (1.07x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Recursion Pharmaceuticals Inc's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Recursion Pharmaceuticals Inc (2019–2025)
The table below shows the annual total assets of Recursion Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.47 Billion | +1.76% |
| 2024-12-31 | $1.45 Billion | +121.60% |
| 2023-12-31 | $653.70 Million | -6.79% |
| 2022-12-31 | $701.29 Million | +14.90% |
| 2021-12-31 | $610.35 Million | +104.41% |
| 2020-12-31 | $298.58 Million | +194.37% |
| 2019-12-31 | $101.43 Million | -- |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenom… Read more